Exploring how African genetic variations affect Alzheimer's disease risk
Official title: Interrogating the protective effect of African APOE alleles on Alzheimer's disease risk through pleiotropy
Funded at University of Washington · NIH-10980335 · Data updated 2026-11-12
This study is looking at how certain genetic traits from African ancestry might affect the risk of developing Alzheimer's disease, specifically in African American and Caribbean communities, to help find ways to prevent the disease for those who might be at higher risk.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $233,250 |
| NIH project number | 1R21AG089267-01 |
| Project ID | NIH-10980335 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals of African descent, particularly those with a family history of Alzheimer's disease.
✕Less likely to help
Patients who do not have African ancestry or those without a family history of Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates the relationship between specific African-derived genetic variations in the APOE gene and the risk of developing Alzheimer's disease (AD). By analyzing genetic data from African American and Caribbean populations, the study aims to identify which genetic variants contribute to a lower risk of AD. The researchers will also explore how these genetic factors influence biological processes related to AD, such as lipid metabolism and inflammation. This work could provide insights into the genetic basis of AD and help tailor prevention strategies for at-risk populations.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and prevention strategies for Alzheimer's disease in African and African American populations.
How similar studies have gone: Previous research has shown promising results in understanding the genetic factors influencing Alzheimer's disease risk in diverse populations, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Blue, Elizabeth Eloyce — University of Washington
- Study coordinator: Blue, Elizabeth Eloyce
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.